Interleukin-22 Might Act as a Double-Edged Sword in Type 2 Diabetes and Coronary Artery Disease

<div>Serum levels of five Th17-related cytokines among the study groups. The serum levels of five Th17-related cytokines were determined in the control, type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), and T2DM-CAD groups by using the Cytokines Quantitative Assays. Values are presented as medians (25th and 75th percentiles). <svg height="15.672pt" id="M39" style="vertical-align:-3.834pt" version="1.1" viewbox="-0.0498162 -11.838 51.9505 15.672" width="51.9505pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M724 428H489V396C558 388 570 377 552 332C533 288 517 255 494 220C431 283 362 343 329 370C366 395 388 414 407 430C430 449 449 478 449 518C449 598 382 657 300 657C209 657 133 590 133 499C133 444 161 403 204 363C116 299 54 261 54 169C54 81 127 -14 255 -14C327 -14 396 20 468 116C500 84 539 36 553 22C565 8 621 -14 677 -19L684 -8C652 49 565 147 521 191C557 244 580 284 607 323C640 373 654 388 724 396V428ZM288 619C337 619 373 573 373 516C373 465 347 427 300 392C236 437 207 471 207 522C207 579 241 619 288 619ZM282 57C214 57 142 105 142 197C142 246 168 291 233 338C329 262 390 203 441 146C409 101 349 57 282 57Z" id="g58-36"></path><glyph.data ascent="1007" descent="-369" horiz-adv-x="719" vert-adv-y="719"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,7.111,.966)"><path d="M600 480C600 590 528 650 384 650H143L137 622C222 614 225 607 210 531L130 127C113 41 106 36 23 28L17 0H294L300 28C204 36 195 42 212 127L243 284L314 263C327 263 339 263 352 264C465 271 600 337 600 480ZM508 481C508 351 402 304 329 304C289 304 265 311 250 317L295 559C302 594 310 606 323 611C335 616 350 619 367 619C455 619 508 573 508 481Z" id="g113-81"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="617" vert-adv-y="617"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,18.794,0)"><path d="M512 -3V55L134 254V256L512 456V514L75 281V230L512 -3Z" id="g117-91"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="587" vert-adv-y="587"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,30.057,0)"><path d="M241 635C89 635 35 457 35 312C35 153 89 -12 240 -12C390 -12 443 166 443 312C443 466 390 635 241 635ZM238 602C329 602 354 454 354 312C354 172 330 22 240 22C152 22 124 173 124 313S148 602 238 602Z" id="g113-49"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="480" vert-adv-y="480"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,36.297,0)"><path d="M113 -12C146 -12 170 11 170 46C170 78 146 103 114 103S58 78 58 46C58 11 82 -12 113 -12Z" id="g113-47"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="228" vert-adv-y="228"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,39.261,0)"><path d="M241 635C89 635 35 457 35 312C35 153 89 -12 240 -12C390 -12 443 166 443 312C443 466 390 635 241 635ZM238 602C329 602 354 454 354 312C354 172 330 22 240 22C152 22 124 173 124 313S148 602 238 602Z" id="g113-49"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="480" vert-adv-y="480"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,45.501,0)"><path d="M153 550H386L412 615L406 623H120L82 318C104 327 142 338 184 338C294 338 347 275 347 187C347 112 305 39 221 39C160 39 119 71 97 89C88 97 80 96 71 90C59 80 50 67 49 57C48 45 52 36 66 23C80 9 123 -12 169 -12C221 -11 288 15 342 59C403 109 431 165 431 225C431 308 366 395 238 395C212 395 165 379 127 364L153 550Z" id="g113-54"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="480" vert-adv-y="480"></glyph.data></g></svg>; <svg height="15.672pt" id="M40" style="vertical-align:-3.834pt" version="1.1" viewbox="-0.0498162 -11.838 58.5636 15.672" width="58.5636pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M724 428H489V396C558 388 570 377 552 332C533 288 517 255 494 220C431 283 362 343 329 370C366 395 388 414 407 430C430 449 449 478 449 518C449 598 382 657 300 657C209 657 133 590 133 499C133 444 161 403 204 363C116 299 54 261 54 169C54 81 127 -14 255 -14C327 -14 396 20 468 116C500 84 539 36 553 22C565 8 621 -14 677 -19L684 -8C652 49 565 147 521 191C557 244 580 284 607 323C640 373 654 388 724 396V428ZM288 619C337 619 373 573 373 516C373 465 347 427 300 392C236 437 207 471 207 522C207 579 241 619 288 619ZM282 57C214 57 142 105 142 197C142 246 168 291 233 338C329 262 390 203 441 146C409 101 349 57 282 57Z" id="g58-36"></path><glyph.data ascent="1007" descent="-369" horiz-adv-x="719" vert-adv-y="719"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,6.589,-5.741)"><path d="M724 428H489V396C558 388 570 377 552 332C533 288 517 255 494 220C431 283 362 343 329 370C366 395 388 414 407 430C430 449 449 478 449 518C449 598 382 657 300 657C209 657 133 590 133 499C133 444 161 403 204 363C116 299 54 261 54 169C54 81 127 -14 255 -14C327 -14 396 20 468 116C500 84 539 36 553 22C565 8 621 -14 677 -19L684 -8C652 49 565 147 521 191C557 244 580 284 607 323C640 373 654 388 724 396V428ZM288 619C337 619 373 573 373 516C373 465 347 427 300 392C236 437 207 471 207 522C207 579 241 619 288 619ZM282 57C214 57 142 105 142 197C142 246 168 291 233 338C329 262 390 203 441 146C409 101 349 57 282 57Z" id="g58-36"></path><glyph.data ascent="1007" descent="-369" horiz-adv-x="719" vert-adv-y="719"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,13.724,.966)"><path d="M600 480C600 590 528 650 384 650H143L137 622C222 614 225 607 210 531L130 127C113 41 106 36 23 28L17 0H294L300 28C204 36 195 42 212 127L243 284L314 263C327 263 339 263 352 264C465 271 600 337 600 480ZM508 481C508 351 402 304 329 304C289 304 265 311 250 317L295 559C302 594 310 606 323 611C335 616 350 619 367 619C455 619 508 573 508 481Z" id="g113-81"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="617" vert-adv-y="617"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,25.407,0)"><path d="M512 -3V55L134 254V256L512 456V514L75 281V230L512 -3Z" id="g117-91"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="587" vert-adv-y="587"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,36.67,0)"><path d="M241 635C89 635 35 457 35 312C35 153 89 -12 240 -12C390 -12 443 166 443 312C443 466 390 635 241 635ZM238 602C329 602 354 454 354 312C354 172 330 22 240 22C152 22 124 173 124 313S148 602 238 602Z" id="g113-49"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="480" vert-adv-y="480"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,42.91,0)"><path d="M113 -12C146 -12 170 11 170 46C170 78 146 103 114 103S58 78 58 46C58 11 82 -12 113 -12Z" id="g113-47"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="228" vert-adv-y="228"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,45.874,0)"><path d="M241 635C89 635 35 457 35 312C35 153 89 -12 240 -12C390 -12 443 166 443 312C443 466 390 635 241 635ZM238 602C329 602 354 454 354 312C354 172 330 22 240 22C152 22 124 173 124 313S148 602 238 602Z" id="g113-49"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="480" vert-adv-y="480"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,52.114,0)"><path d="M384 0V27C293 34 287 42 287 114V635C232 613 172 594 109 583V559L157 557C201 555 205 550 205 499V114C205 42 199 34 109 27V0H384Z" id="g113-50"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="480" vert-adv-y="480"></glyph.data></g></svg> versus control group.</div>

Mediators of Inflammation

fig1

Figure 1

Figure 1: Interleukin-22 Might Act as a Double-Edged Sword in Type 2 Diabetes and Coronary Artery Disease 